Isaac Ashkenazi is a partner in Paul Hastings’ Life Sciences IP Group, where he focuses his practice on complex intellectual property disputes primarily in the pharmaceutical, chemistry, and biotechnology fields. He has successfully represented some of the world’s leading life sciences companies in high-stakes patent disputes involving their critical drug products in various forums, including the PTAB, district courts, appeals courts, and arbitrations. Mr. Ashkenazi has experience with a broad range of technologies, including pharmaceutical compounds, proteins, polymers, formulations, and chemical and synthetic processes, and a wide variety of therapeutics, including vaccines, oncology drugs, Parkinson’s medications, proton pump inhibitors, sleep agents, respiratory agents, antiemetics, and cholesterol-lowering and antidiabetic agents.

• Recognized in Chambers USA, Intellectual Property: Patent (2023).
• Ranked by IAM Patent 1000 as a leading patent professional (2022-2023).
• Recognized as an IP Star by Managing Intellectual Property (2023).
• The Legal 500's Intellectual Property - Patents: Litigation (Full Coverage) (2021, 2023).
• Named a Rising Star in Life Sciences by Law360 in 2018 for several high-stakes wins, including invalidating a key patent for Humira®, the world’s best-selling drug.
• Recognized in The Legal 500 for two successful IPR petitions resulting in rulings that method-of-treatment claims covering the drug product Humira® would have been obvious.
• Named American Lawyer’s 2018 Transatlantic IP Team of the Year for leading a major pharmaceutical litigation through fact, expert and Markman phases, and obtaining six walk-away consent judgments.
• 2017 Law360 Life Sciences Practice Group of the Year.
• Two-time Legal Lion, Law360.

• Benjamin N. Cardozo School of Law, J.D. (concentration in Intellectual Property), 2005
• The Cooper Union, B.E. in Chemical Engineering, 2002